Latest On Capricor Therapeutics, Inc (CAPR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 07:12 EST | News | Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 17:36 EST | News | Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.01, revenue of $2.98M beats by $2.48M | N/A | |
| 2023-03-16 00:26 EST | News | Capricor Therapeutics GAAP EPS of -$0.31 beats by $0.03, revenue of $0.96M beats by $0.96M | N/A | |
| 2023-03-16 00:26 EST | News | Capricor Therapeutics, Inc. (CAPR) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-14 18:00 EST | News | Capricor Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-01-25 14:41 EST | News | Capricor stock falls amid data for duchenne muscular dystrophy study | N/A | |
| 2022-11-11 07:18 EST | News | Capricor Therapeutics GAAP EPS of -$0.26 beats by $0.05, revenue of $1.59M beats by $1.45M | N/A | |
| 2022-11-11 07:17 EST | News | Capricor Therapeutics, Inc. (CAPR) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-09 21:36 EST | News | Capricor Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-08-12 00:03 EST | News | Capricor stock rises 16% after update on muscular dystrophy treatment, Q2 results | N/A | |
| 2022-08-11 07:06 EST | News | Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03 | N/A | |
| 2022-08-11 07:06 EST | News | Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call Transcript | N/A | |
| 2022-08-09 20:06 EST | News | Capricor Therapeutics Q2 Earnings Preview | N/A | |
| 2022-06-28 01:00 EST | News | Capricor posts statistically significant data for DMD candidate in open-label trial | N/A | |
| 2022-05-11 01:15 EST | News | Capricor Therapeutics GAAP EPS of -$0.32 | N/A | |
| 2022-05-11 01:15 EST | News | Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-03-28 16:40 EST | News | Capricor Therapeutics down 24% following COVID-19 mid-stage trial results (updated) | N/A | |
| 2022-03-11 08:26 EST | News | Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-01-25 10:04 EST | News | Capricor jumps 12% after CAP-1002 commercialization deal in U.S. for treatment of DMD | N/A | |
| 2021-12-13 16:39 EST | News | Capricor Therapeutics provides key updates on its COVID-19 vaccine programs | N/A | |
| 2021-11-10 04:09 EST | News | Capricor Therapeutics EPS beats by $0.06 | N/A | |
| 2021-11-10 04:08 EST | News | Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-09 05:10 EST | News | Capricor Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-09-25 19:24 EST | News | Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result | N/A | |
| 2021-09-24 23:37 EST | News | Capricor jumps 17% on positive CAP-1002 data from mid-stage duchenne muscular dystrophy study | N/A | |
| 2021-09-02 16:11 EST | News | Capricor shares up 6 % as it will present final data on muscular dystrophy candidate late September | N/A | |
| 2021-08-13 10:16 EST | News | Capricor Therapeutics EPS beats by $0.02, misses on revenue | N/A | |
| 2021-08-13 10:15 EST | News | Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-20 22:51 EST | News | Capricor Therapeutics slumps 9% on $75M stock offering | N/A | |
| 2021-04-30 07:24 EST | News | Capricor shares rise on license agreement with Johns Hopkins University | N/A | |
| 2021-03-18 04:19 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-13 03:16 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-12 07:18 EST | Earnings Estimate | An EPS average of -$1.07 is estimated for the 2022 year. | Sell | |
| 2021-03-12 00:43 EST | News | Capricor Therapeutics EPS misses by $0.01 | N/A | |
| 2021-03-12 00:43 EST | News | Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-09 13:49 EST | News | Capricor Therapeutics updates on COVID-19 vaccine pre-clinical study | N/A | |
| 2021-02-10 08:09 EST | News | Capricor Therapeutics - Shockingly Undervalued With Imminent Catalysts In Play | N/A | |
| 2021-02-01 10:47 EST | News | Capricor signs intellectual property license for COVID-19 serology test platform | N/A | |
| 2021-01-25 03:17 EST | Analyst Rating | The Analyst Target Price has increased from $10.5 to $12. | Buy | |
| 2021-01-20 01:02 EST | News | Capricor announces positive findings from collaboration with Cedars-Sinai Medical Center researchers | N/A | |
| 2021-01-12 20:54 EST | News | Capricor and Lonza tie up in DMD development | N/A | |
| 2020-12-13 03:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 15:54 EST | News | Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19 | N/A | |
| 2020-11-18 03:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 03:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-15 11:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-14 03:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-13 22:56 EST | News | Capricor Therapeutics, Inc's (CAPR) CEO Linda Marbán on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-12 19:06 EST | News | Capricor Therapeutics reports Q3 results | N/A | |
| 2020-11-01 17:26 EST | Financials | Company financials have been released. | Neutral | |
About Capricor Therapeutics, Inc (CAPR):
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. Capricor collaborates with Lonza for the development of CAP-1002, its cell therapy candidate for the treatment of Duchenne muscular dystrophy and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
General
- Name Capricor Therapeutics, Inc
- Symbol CAPR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Last Split Factor1:10
- Last Split Date2019-06-05
- Fiscal Year EndDecember
- IPO Date2007-02-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.capricor.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 149.52
- Price/Book (Most Recent Quarter) 4.13
- Enterprise Value Revenue 190.86
- Enterprise Value EBITDA 0.03
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.00
- Next Year EPS Estimate -$1.06
- Operating Margin -4413%
- Return on Assets -37%
- Return on Equity -78%
- Revenue 310250
- Earnings Per Share -$3.74
- Revenue Per Share $0.02
- Gross Profit -8146750
- Quarterly Earnings Growth -74%
View More
Highlights
- Market Capitalization 118.78 million
- EBITDA -11929662
- Analyst Target Price $12
- Book Value Per Share $1.37
View More
Share Statistics
- Shares Outstanding 22.8 million
- Shares Float 19.99 million
- % Held by Insiders 253%
- % Held by Institutions 6.2%
- Shares Short 345150
- Shares Short Prior Month 489136
- Short Ratio 0.36
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 6.47
- 52 Week High $12.32
- 52 Week Low $0.96
- 50 Day Moving Average 6.37
- 200 Day Moving Average 5.05
View More
Dividends
- Dividend Date 2019-06-05
- ExDividend Date N/A
- Dividend Yield 0%
View More
Capricor Therapeutics, Inc (CAPR) Dividend Calendar:
CAPR's last dividend payment was made to shareholders on June 5, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Capricor Therapeutics, Inc (CAPR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$0.21 | -$0.20 | -5% |
| 2020-09-30 | 2020-11-12 | $N/A | -$0.20 | -$0.37 | 45.95% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.23 | -$0.34 | 32.35% |
| 2020-03-31 | 2020-05-13 | $185693 | -$0.30 | -$0.36 | 16.67% |
| 2019-12-31 | 2020-03-18 | $222100 | -$0.34 | -$0.34 | 0% |
| 2019-09-30 | 2019-11-07 | $142071 | -$0.43 | -$0.68 | 36.76% |
| 2019-06-30 | 2019-08-06 | $410353 | -$0.59 | -$0.80 | 26.25% |
| 2019-03-31 | 2019-05-13 | $230504 | -$0.80 | -$1.10 | 27.27% |
| 2018-12-31 | 2019-03-28 | $648082 | -$1.10 | -$1.60 | 31.25% |
| 2018-09-30 | 2018-11-13 | $219247 | -$1.40 | -$1.45 | 3.45% |
| 2018-06-30 | 2018-08-09 | $403960 | -$1.40 | -$1.25 | -12% |
| 2018-03-31 | 2018-05-10 | $400066 | -$1.40 | -$1.20 | -16.67% |
| 2017-12-31 | 2018-03-14 | $475000 | $4.20 | -$1.00 | 520% |
| 2017-09-30 | 2017-11-08 | $314000 | -$1.20 | -$1.90 | 36.84% |
| 2017-06-30 | 2017-08-10 | $996000 | -$1.60 | -$1.80 | 11.11% |
| 2017-03-31 | 2017-05-15 | $881000 | -$1.70 | -$1.50 | -13.33% |
| 2016-12-31 | 2017-03-15 | $907000 | -$2.10 | -$2.70 | 22.22% |
| 2016-09-30 | 2016-11-10 | $747000 | -$2.90 | -$2.65 | -9.43% |
| 2016-06-30 | 2016-08-15 | $1.13 million | -$2.60 | -$2.40 | -8.33% |
| 2016-03-31 | 2016-05-12 | $1.22 million | -$2.60 | -$1.90 | -36.84% |
| 2015-12-31 | 2016-03-17 | $1.12 million | -$2.10 | -$1.90 | -10.53% |
| 2015-09-30 | 2015-11-12 | $1.32 million | -$0.18 | -$0.26 | 30.77% |
| 2015-06-30 | 2015-08-13 | $1.29 million | -$0.19 | -$0.26 | 26.92% |
| 2015-03-31 | 2015-05-12 | $1.79 million | -$0.23 | -$0.14 | -64.29% |
| 2014-12-31 | 2015-03-16 | $1.4 million | -$0.16 | -$0.13 | -23.08% |
| 2014-09-30 | 2014-11-14 | $1.3 million | -$0.13 | -$0.22 | 40.91% |
| 2014-06-30 | 2014-08-14 | $1.04 million | -$1.31 | ||
| 2014-03-31 | 2014-05-15 | $1.04 million | -$1.04 | ||
| 2013-12-31 | 2014-03-17 | $503233 | -$6.39 | ||
| 2013-09-30 | 2013-11-15 | $80000 | -$4.02 | ||
| 2013-06-30 | 2013-08-15 | $190000 | -$6.94 | ||
| 2013-03-31 | 2013-06-21 | $233000 | -$5.61 | ||
| 2012-12-31 | 2013-03-12 | $2.03 million | -$2.39 | ||
| 2012-09-30 | 2012-11-12 | $-2423235 | -$6.57 | ||
| 2012-06-30 | 2012-08-13 | $N/A | -$4.11 | ||
| 2012-03-31 | 2012-05-15 | $195500 | -$20.00 | -$15.00 | -33.33% |
| 2011-12-31 | 2012-03-13 | -$22.29 | |||
| 2011-09-30 | 2011-11-14 | $813000 | -$15.00 | -$7.50 | -100% |
| 2011-06-30 | 2011-08-15 | $346000 | -$15.00 | -$5.00 | -200% |
| 2011-03-31 | 2011-05-16 | -$15.00 | -$10.00 | -50% | |
| 2010-12-31 | 2011-03-14 | -$10.00 | -$21.67 | 53.85% | |
| 2010-09-30 | 2010-11-12 | -$25.00 | -$23.33 | -7.16% | |
| 2010-06-30 | 2010-08-16 | -$25.00 | -$33.33 | 24.99% | |
| 2010-03-31 | 2010-05-14 | -$35.00 | -$28.33 | -23.54% | |
| 2009-12-31 | 2010-03-03 | -$30.00 | -$25.00 | -20% | |
| 2009-09-30 | 2009-11-12 | -$40.00 | -$25.00 | -60% | |
| 2009-06-30 | 2009-08-13 | -$50.00 | -$37.50 | -33.33% | |
| 2009-03-31 | 2009-05-14 | -$35.00 | -$58.33 | 40% | |
| 2008-12-31 | 2009-03-09 | -$60.00 | -$65.00 | 7.69% | |
| 2008-09-30 | 2008-11-13 | -$70.00 | -$78.33 | 10.63% | |
| 2008-06-30 | 2008-08-14 | -$80.00 | -$57.50 | -39.13% | |
| 2008-03-31 | 2008-05-15 | -$65.00 | -$55.00 | -18.18% | |
| 2007-12-31 | 2008-03-13 | -$50.00 | -$95.00 | 47.37% | |
| 2007-09-30 | 2007-11-28 | -$173.63 | |||
| 2006-12-31 | 2006-12-31 | -$6.69 | |||
| 2006-09-30 | 2006-09-30 | -$23.16 | |||
| 2006-06-30 | 2006-06-30 | -$5.98 | |||
| 2006-03-31 | 2006-03-31 | -$4.79 | |||
| 2005-09-30 | 2005-09-30 | -$2.28 | |||
| 2005-06-30 | 2005-06-30 | -$1.95 | |||
| 2005-03-31 | 2005-03-31 | -$3.57 | |||
| 2004-12-31 | 2004-12-31 | -$6.14 | |||
| 2004-09-30 | 2004-09-30 | -$2.33 | |||
| 2004-06-30 | 2004-06-30 | -$1.90 | |||
| 2004-03-31 | 2004-03-31 | -$1.64 | |||
| 2003-12-31 | 2003-12-31 | -$3.57 | |||
| 2003-09-30 | 2003-09-30 | -$0.06 | |||
| 2003-06-30 | 2003-06-30 | -$4.61 | |||
| 2003-03-31 | 2003-03-31 | -$2.46 | |||
| 2002-12-31 | 2002-12-31 | -$2.50 | |||
| 2002-09-30 | 2002-09-30 | -$5.67 | |||
| 2002-06-30 | 2002-06-30 | -$6.25 |
Capricor Therapeutics, Inc (CAPR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 1.16 million | 828749 |
| Income Before Tax | N/A | N/A | N/A | -2.08 million | -1.47 million |
| Selling General Administrative | N/A | N/A | N/A | 1.14 million | 876720 |
| Gross Profit | N/A | N/A | N/A | N/A | 222100 |
| Ebit | N/A | N/A | N/A | -2.07 million | -1.48 million |
| Operating Income | N/A | N/A | N/A | -2.11 million | -1.48 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | 185693 | 222100 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | 22690 | 13951 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -2.08 million | -1.47 million |
| Net Income Applicable to Common Shares | -4.18 million | -3.91 million | -3.48 million | N/A | -1.47 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | 426904 | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | 5.99 million | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | N/A | 149635 | N/A | N/A |
| Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Total Cash from Operating Activities | N/A | N/A | -1.22 million | N/A | N/A |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | 287807 | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 5.78 million | 5.47 million | N/A | N/A |
| Total Stockholder Equity | N/A | 30.41 million | 31.65 million | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | 36.19 million | 37.13 million | N/A | N/A |
| Common Stock | 20577 | 20212 | N/A | 9189 | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -88.04 million | -83.86 million | N/A | -76.47 million | N/A |
| Other Liabilities | 3.38 million | 3.38 million | N/A | 3.38 million | N/A |
| Other Assets | 88701 | 88701 | N/A | 107380 | N/A |
| Cash | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | 2.97 million | 2.28 million | N/A | N/A | N/A |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 850847 | 603719 | N/A | 410913 | N/A |
| Total Current Assets | 33.68 million | 35.49 million | 36.25 million | N/A | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 28.2 million | 30.4 million | 9.59 million | 9.59 million | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.72 million | 2.06 million | N/A | N/A | N/A |
Capricor Therapeutics, Inc (CAPR) Chart:
Capricor Therapeutics, Inc (CAPR) News:
Below you will find a list of latest news for Capricor Therapeutics, Inc (CAPR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Capricor Therapeutics, Inc (CAPR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 4.8 | CALL | 0 | 0 | 506.83 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.75 | CALL | 10 | 63 | 129.6 | TRUE | -0.25 | -0.25 |
| 2024-05-17 | 7.5 | 0.2 | CALL | 1 | 162 | 141.85 | FALSE | -0.15 | -0.43 |
| 2024-05-17 | 10 | 0.1 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0.05 | CALL | 0 | 52 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.55 | PUT | 5 | 49 | 160.72 | FALSE | 0.55 | 0 |
| 2024-05-17 | 7.5 | 1.93 | PUT | 0 | 8 | 164.78 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 295.95 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 6 | PUT | 0 | 1 | 371.46 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 3.9 | CALL | 0 | 273 | 355.22 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0.95 | CALL | 4 | 847 | 109.59 | TRUE | -0.19 | -0.17 |
| 2024-06-21 | 7.5 | 0.55 | CALL | 0 | 1119 | 129.8 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0.65 | CALL | 0 | 56 | 136.59 | FALSE | 0 | 0 |
| 2024-06-21 | 12.5 | 0.3 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.2 | PUT | 0 | 125 | 163.18 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0.75 | PUT | 1 | 277 | 96.41 | FALSE | 0.75 | 0 |
| 2024-06-21 | 7.5 | 2 | PUT | 0 | 45 | 109.7 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 4.58 | PUT | 0 | 1 | 226.94 | TRUE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 252.95 | TRUE | 0 | 0 |
| 2024-09-20 | 2.5 | 3.9 | CALL | 0 | 704 | 119.2 | TRUE | 0 | 0 |
| 2024-09-20 | 5 | 1.35 | CALL | 2 | 298 | 100.12 | TRUE | -0.45 | -0.25 |
| 2024-09-20 | 7.5 | 1.1 | CALL | 0 | 711 | 103.8 | FALSE | 0 | 0 |
| 2024-09-20 | 10 | 0.4 | CALL | 1 | 56 | 104.16 | FALSE | 0.4 | 0 |
| 2024-09-20 | 12.5 | 0.65 | CALL | 0 | 17 | 125.02 | FALSE | 0 | 0 |
| 2024-09-20 | 2.5 | 0.25 | PUT | 0 | 0 | 115.54 | FALSE | 0 | 0 |
| 2024-09-20 | 5 | 1.25 | PUT | 4 | 47 | 104.42 | FALSE | 0.2 | 0.19 |
| 2024-09-20 | 7.5 | 2.55 | PUT | 0 | 5 | 104.51 | TRUE | 0 | 0 |
| 2024-09-20 | 10 | 0 | PUT | 0 | 0 | 131.11 | TRUE | 0 | 0 |
| 2024-09-20 | 12.5 | 0 | PUT | 0 | 0 | 165.36 | TRUE | 0 | 0 |
| 2024-12-20 | 2.5 | 0 | CALL | 0 | 0 | 105.59 | TRUE | 0 | 0 |
| 2024-12-20 | 5 | 0 | CALL | 0 | 0 | 87.6 | TRUE | 0 | 0 |
| 2024-12-20 | 7.5 | 0 | CALL | 0 | 0 | 190.46 | FALSE | 0 | 0 |
| 2024-12-20 | 10 | 0 | CALL | 0 | 0 | 210.32 | FALSE | 0 | 0 |
| 2024-12-20 | 2.5 | 0 | PUT | 0 | 0 | 516.61 | FALSE | 0 | 0 |
| 2024-12-20 | 5 | 0 | PUT | 0 | 0 | 171.96 | FALSE | 0 | 0 |
| 2024-12-20 | 7.5 | 0 | PUT | 0 | 0 | 79.74 | TRUE | 0 | 0 |
| 2024-12-20 | 10 | 0 | PUT | 0 | 0 | 90.91 | TRUE | 0 | 0 |
Latest CAPR Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:58 PM EST | 62 | $3.88 |
| Jun 13, 2022 7:58 PM EST | 5 | $3.8 |
| Jun 13, 2022 7:59 PM EST | 100 | $3.8 |
| Jun 13, 2022 7:59 PM EST | 100 | $3.79 |
| Jun 13, 2022 7:59 PM EST | 50 | $3.79 |
Capricor Therapeutics, Inc (CAPR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-17 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/0001104659-20-074227-index.htm |
| 2018-10-31 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133869/000000000018034036/0000000000-18-034036-index.htm |
| 2019-12-09 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133869/000000000019016215/0000000000-19-016215-index.htm |
| 2020-05-14 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1133869/000000000020004293/0000000000-20-004293-index.htm |
| 2019-12-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1133869/000091957419007837/0000919574-19-007837-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919061080/0001104659-19-061080-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465919061773/0001104659-19-061773-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919063785/0001104659-19-063785-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919064252/0001104659-19-064252-index.htm |
| 2019-12-05 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919070066/0001104659-19-070066-index.htm |
| 2019-12-13 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919072396/0001104659-19-072396-index.htm |
| 2019-12-13 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919072626/0001104659-19-072626-index.htm |
| 2019-12-13 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133869/000110465919072629/0001104659-19-072629-index.htm |
| 2019-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919073161/0001104659-19-073161-index.htm |
| 2019-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919073600/0001104659-19-073600-index.htm |
| 2019-12-19 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074049/0001104659-19-074049-index.htm |
| 2019-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074247/0001104659-19-074247-index.htm |
| 2019-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074513/0001104659-19-074513-index.htm |
| 2019-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074514/0001104659-19-074514-index.htm |
| 2019-12-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074516/0001104659-19-074516-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022098/0001104659-20-022098-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022099/0001104659-20-022099-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022100/0001104659-20-022100-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022101/0001104659-20-022101-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022102/0001104659-20-022102-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022103/0001104659-20-022103-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022104/0001104659-20-022104-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022105/0001104659-20-022105-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920022110/0001104659-20-022110-index.htm |
| 2020-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920031538/0001104659-20-031538-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920034994/0001104659-20-034994-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920035320/0001104659-20-035320-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920038468/0001104659-20-038468-index.htm |
| 2020-03-27 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133869/000110465920039272/0001104659-20-039272-index.htm |
| 2020-04-17 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1133869/000110465920047790/0001104659-20-047790-index.htm |
| 2020-05-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920056292/0001104659-20-056292-index.htm |
| 2020-05-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465920056303/0001104659-20-056303-index.htm |
| 2020-05-07 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000110465920058189/0001104659-20-058189-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920058192/0001104659-20-058192-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920060449/0001104659-20-060449-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920060930/0001104659-20-060930-index.htm |
| 2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920061570/0001104659-20-061570-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920062419/0001104659-20-062419-index.htm |
| 2020-05-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133869/000110465920062458/0001104659-20-062458-index.htm |
| 2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465920062698/0001104659-20-062698-index.htm |
| 2020-05-19 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465920063822/0001104659-20-063822-index.htm |
| 2020-05-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920066994/0001104659-20-066994-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071410/0001104659-20-071410-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071413/0001104659-20-071413-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071415/0001104659-20-071415-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071417/0001104659-20-071417-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071419/0001104659-20-071419-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071420/0001104659-20-071420-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071421/0001104659-20-071421-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071423/0001104659-20-071423-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920071426/0001104659-20-071426-index.htm |
| 2020-06-17 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1133869/000110465920074227/0001104659-20-074227-index.htm |
| 2020-07-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920087909/0001104659-20-087909-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920091413/0001104659-20-091413-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000110465920092415/0001104659-20-092415-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000110465920098381/0001104659-20-098381-index.htm |
| 2020-09-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000110465920109138/0001104659-20-109138-index.htm |
| 2017-10-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417053252/0001144204-17-053252-index.htm |
| 2017-10-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420417053253/0001144204-17-053253-index.htm |
| 2017-10-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420417053990/0001144204-17-053990-index.htm |
| 2017-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417057263/0001144204-17-057263-index.htm |
| 2017-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420417058512/0001144204-17-058512-index.htm |
| 2017-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417059277/0001144204-17-059277-index.htm |
| 2017-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417061266/0001144204-17-061266-index.htm |
| 2017-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417063248/0001144204-17-063248-index.htm |
| 2017-12-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417064330/0001144204-17-064330-index.htm |
| 2017-12-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420417065088/0001144204-17-065088-index.htm |
| 2018-01-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000266/0001144204-18-000266-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000853/0001144204-18-000853-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000854/0001144204-18-000854-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000856/0001144204-18-000856-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000857/0001144204-18-000857-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000859/0001144204-18-000859-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000860/0001144204-18-000860-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000861/0001144204-18-000861-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000862/0001144204-18-000862-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000863/0001144204-18-000863-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000864/0001144204-18-000864-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000865/0001144204-18-000865-index.htm |
| 2018-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000868/0001144204-18-000868-index.htm |
| 2018-02-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418005594/0001144204-18-005594-index.htm |
| 2018-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418009043/0001144204-18-009043-index.htm |
| 2018-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418014063/0001144204-18-014063-index.htm |
| 2018-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418014635/0001144204-18-014635-index.htm |
| 2018-03-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133869/000114420418016468/0001144204-18-016468-index.htm |
| 2018-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1133869/000114420418022479/0001144204-18-022479-index.htm |
| 2018-05-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418025173/0001144204-18-025173-index.htm |
| 2018-05-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418027107/0001144204-18-027107-index.htm |
| 2018-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420418027786/0001144204-18-027786-index.htm |
| 2018-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418033770/0001144204-18-033770-index.htm |
| 2018-07-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420418039922/0001144204-18-039922-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418043267/0001144204-18-043267-index.htm |
| 2018-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420418043686/0001144204-18-043686-index.htm |
| 2018-10-24 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000114420418055035/0001144204-18-055035-index.htm |
| 2018-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418056889/0001144204-18-056889-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418059340/0001144204-18-059340-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420418059980/0001144204-18-059980-index.htm |
| 2018-12-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420418066148/0001144204-18-066148-index.htm |
| 2019-01-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419000167/0001144204-19-000167-index.htm |
| 2019-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419002173/0001144204-19-002173-index.htm |
| 2019-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419005129/0001144204-19-005129-index.htm |
| 2019-03-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419016629/0001144204-19-016629-index.htm |
| 2019-03-29 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419016787/0001144204-19-016787-index.htm |
| 2019-04-01 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419017194/0001144204-19-017194-index.htm |
| 2019-04-19 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1133869/000114420419020402/0001144204-19-020402-index.htm |
| 2019-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1133869/000114420419022029/0001144204-19-022029-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419025600/0001144204-19-025600-index.htm |
| 2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419026041/0001144204-19-026041-index.htm |
| 2019-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419029338/0001144204-19-029338-index.htm |
| 2019-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419029669/0001144204-19-029669-index.htm |
| 2019-06-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419031589/0001144204-19-031589-index.htm |
| 2019-07-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419034627/0001144204-19-034627-index.htm |
| 2019-07-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1133869/000114420419034690/0001144204-19-034690-index.htm |
| 2019-07-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419034770/0001144204-19-034770-index.htm |
| 2019-07-17 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1133869/000114420419034954/0001144204-19-034954-index.htm |
| 2019-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419035262/0001144204-19-035262-index.htm |
| 2019-07-22 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419035263/0001144204-19-035263-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419037875/0001144204-19-037875-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038387/0001144204-19-038387-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038994/0001144204-19-038994-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038995/0001144204-19-038995-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038996/0001144204-19-038996-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038997/0001144204-19-038997-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038998/0001144204-19-038998-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419038999/0001144204-19-038999-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419039000/0001144204-19-039000-index.htm |
| 2019-08-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1133869/000114420419039001/0001144204-19-039001-index.htm |
| 2019-08-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419040654/0001144204-19-040654-index.htm |
| 2019-08-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419042160/0001144204-19-042160-index.htm |
| 2019-08-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1133869/000114420419042161/0001144204-19-042161-index.htm |
| 2019-10-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1133869/000114420419047446/0001144204-19-047446-index.htm |
| 2019-07-18 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133869/999999999519001637/9999999995-19-001637-index.htm |
| 2019-12-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133869/999999999519002841/9999999995-19-002841-index.htm |
| 2020-05-19 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1133869/999999999520001205/9999999995-20-001205-index.htm |
| 2018-04-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1133869/999999999718004982/9999999997-18-004982-index.htm |
| 2018-08-29 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1133869/999999999718007502/9999999997-18-007502-index.htm |
Capricor Therapeutics, Inc (CAPR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Capricor Therapeutics, Inc (CAPR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 253%Institutional Ownership: 620%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2017-10-23 | Louis Manzo | Director | Buy | 20,748.00 | 0.16 | 3,319.68 | 159,132.00 | https://www.sec.gov/Archives/edgar/data/1133869/000114420417053990/0001144204-17-053990-index.htm |
| 2019-12-17 | Frank Litvack | Director | Buy | 20,391.00 | 20,391.00 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074516/0001104659-19-074516-index.htm | ||
| 2017-12-22 | Rachel Smith | Vice President of R&D | Buy | 20,748.00 | 0.16 | 3,319.68 | 20,748.00 | https://www.sec.gov/Archives/edgar/data/1133869/000114420418000868/0001144204-18-000868-index.htm |
| 2019-12-17 | David B Musket | Director | Buy | 20,391.00 | 22,891.00 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074514/0001104659-19-074514-index.htm | ||
| 2019-12-17 | Louis Manzo | Director | Buy | 20,391.00 | 36,304.00 | https://www.sec.gov/Archives/edgar/data/1133869/000110465919074513/0001104659-19-074513-index.htm | ||
| 2020-09-24 | Louis Manzo | Director | Buy | 8,299.00 | 3.70 | 30,706.30 | 44,603.00 | https://www.sec.gov/Archives/edgar/data/1133869/000110465920109138/0001104659-20-109138-index.htm |
| 2020-07-27 | Linda Marban | CHIEF EXECUTIVE OFFICER | Buy | 41,497.00 | 3.70 | 153,538.90 | 62,367.00 | https://www.sec.gov/Archives/edgar/data/1133869/000110465920087909/0001104659-20-087909-index.htm |